Cogent Biosciences
COGT
30.14
-0.24
-0.79%
Cogent Biosciences
US · COGT
#2052 by market cap
Listed 2016
30.14
-0.24
-0.79%
Live - 5344 symbols - heartbeat 90s ago
· 2026-10-08 07:53
Pre-market
30.10
-0.14%
After-hours
30.14
0.00%
- Market cap
- 5.23B
- P/E (TTM)i
- -13.95
- P/Bi
- 11.18
- EPSi
- -2.16
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on COGT?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Key ratios & quality
- Enterprise valuei
- 4.55B
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.73M | 22.50M | 7.87M | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 7.45M | 10.97M | 17.42M | 19.64M | 26.21M | 34.38M | 43.28M | 63.58M |
| Research & development | 38.29M | 43.71M | 25.74M | 55.91M | 121.63M | 173.76M | 232.66M | 269.78M |
| Operating profit | -36.01M | -32.18M | -35.29M | -75.55M | -147.84M | -208.13M | -275.94M | -333.36M |
| Pretax profit | -34.53M | -31.83M | -74.81M | -72.27M | -140.24M | -192.41M | -255.86M | -328.94M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -34.53M | -31.83M | -74.81M | -72.27M | -140.24M | -192.41M | -255.86M | -328.94M |
| Basic EPS | -6 | -4 | -16 | -2 | -2 | -2 | -2 | -2 |
| Diluted EPS | -5.56 | -4.18 | -16.17 | -1.87 | -1.73 | -1.94 | -1.94 | -2.16 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.90M | 13.38M | 14.37M | 23.93M | 28.24M | 31.83M |
| Research & development | 63.03M | 62.20M | 68.99M | 75.56M | 75.37M | 70.81M |
| Operating profit | -74.93M | -75.58M | -83.36M | -99.49M | -103.61M | -102.64M |
| Pretax profit | -71.99M | -73.53M | -80.93M | -102.49M | -97.35M | -96.41M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -71.99M | -73.53M | -80.93M | -102.49M | -97.35M | -96.41M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.52 | -0.53 | -0.50 | -0.64 | -0.53 | -0.52 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 81.00M | 40.59M | 244.91M | 222.63M | 264.97M | 270.77M | 296.47M | 910.36M |
| Cash & ST investments | 78.59M | 37.42M | 242.19M | 219.68M | 259.28M | 265.71M | 287.08M | 900.77M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 85.93M | 49.42M | 250.92M | 232.09M | 300.81M | 313.44M | 327.90M | 937.61M |
| Total current liabilities | 24.95M | 13.25M | 13.09M | 17.08M | 26.85M | 38.17M | 55.71M | 63.95M |
| Short-term debt | -- | 1.62M | 2.05M | 2.32M | 1.42M | 1.39M | 1.57M | 1.55M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | 222.90M |
| Total liabilities | 25,693,000.00 | 17,661,000.00 | 16,249,000.00 | 17,908,000.00 | 45,075,000.00 | 55,635,000.00 | 71,612,000.00 | 301,236,000.00 |
| Total equity | 60.23M | 31.76M | 234.67M | 214.18M | 255.74M | 257.80M | 256.29M | 636.37M |
| Retained earnings | -92.06M | -123.89M | -198.70M | -270.97M | -411.21M | -603.62M | -859.48M | -1.19B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 252.88M | 245.01M | 397.24M | 910.36M | 877.80M | 804.82M |
| Cash & ST investments | 245.66M | 237.85M | 390.89M | 900.77M | 866.38M | 792.30M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 283.80M | 274.82M | 425.93M | 937.61M | 903.01M | 834.55M |
| Total current liabilities | 49.32M | 58.42M | 62.25M | 63.95M | 57.98M | 59.30M |
| Short-term debt | 1.61M | 1.66M | 1.71M | 1.55M | 1.38M | 1.49M |
| Long-term debt | -- | 43.95M | 44.25M | 222.90M | 223.17M | 223.46M |
| Total liabilities | 64,803,000.00 | 119,781,000.00 | 123,469,000.00 | 301,236,000.00 | 295,313,000.00 | 302,158,000.00 |
| Total equity | 219.00M | 155.04M | 302.46M | 636.37M | 607.69M | 532.39M |
| Retained earnings | -931.47M | -1.00B | -1.09B | -1.19B | -1.29B | -1.38B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.49M | -41.51M | -35.85M | -58.76M | -118.64M | -153.62M | -207.79M | -264.44M |
| Depreciation & amortization | 1.32M | 1.29M | 720.00K | 1.99M | 5.88M | 3.59M | 4.35M | 4.58M |
| Free cash flow | -33.04M | -41.55M | -35.85M | -60.48M | -125.50M | -156.42M | -208.36M | -266.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 71.79M | 0 | 132.73M | 38.01M | 161.95M | 161.82M | 213.34M | 159.32M |
| Ending cash balance | 56.93M | 38.68M | 243.45M | 220.94M | 141.14M | 53.23M | 98.17M | 312.43M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -66.51M | -54.54M | -64.29M | -79.11M | -86.88M | -77.27M |
| Depreciation & amortization | 1.14M | 1.16M | 1.15M | 1.14M | 1.16M | 1.37M |
| Free cash flow | -67.06M | -54.67M | -64.35M | -79.92M | -87.33M | -77.64M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 24.25M | 0 | 215.79M | -80.72M | 45.71M | 0 |
| Ending cash balance | 126.00M | 127.60M | 125.63M | 312.43M | 241.62M | 181.59M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -606.74 | -69.21 | -230.42 | -57.23 | -88.01 | -99.26 | -148.99 | -94.98 |
| ROA %i | -51.17 | -47.04 | -119.34 | -29.93 | -52.63 | -62.65 | -79.79 | -51.99 |
| ROIC %i | -626.99 | -61.70 | -215.07 | -55.75 | -84.47 | -96.43 | -144.27 | -71.78 |
| 5-year avg ROE %i | -- | -- | -- | -- | -210.32 | -108.83 | -124.78 | -97.70 |
| EBIT margin %i | -369.89 | -143.02 | -448.34 | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.25 | 3.06 | 18.70 | 13.04 | 9.87 | 7.09 | 5.32 | 14.23 |
| Quick ratioi | 3.22 | 2.98 | 18.50 | 12.86 | 9.66 | 6.96 | 5.15 | 14.08 |
| Debt / assetsi | 0.00 | 12.20 | 2.08 | 1.36 | 6.53 | 6.01 | 5.33 | 25.47 |
| LT debt / equityi | -- | 13.89 | 2.55 | 0.65 | 9.60 | 8.83 | 10.92 | 43.37 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -106.43 |
| Revenue CAGR (3Y) %i | 48.27 | 52.41 | -1.99 | -- | -- | -- | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -173.15 | -185.53 | -147.70 | -94.98 | -108.39 | -146.55 |
| ROA %i | -70.86 | -80.62 | -72.69 | -51.99 | -59.71 | -68.00 |
| ROIC %i | -165.16 | -154.80 | -128.91 | -71.78 | -81.22 | -96.73 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.13 | 4.19 | 6.38 | 14.23 | 15.14 | 13.57 |
| Quick ratioi | 4.98 | 4.07 | 6.28 | 14.08 | 14.94 | 13.36 |
| Debt / assetsi | 6.02 | 22.07 | 14.22 | 25.47 | 26.43 | 29.27 |
| LT debt / equityi | 13.97 | 125.21 | 30.25 | 43.37 | 43.70 | 51.91 |
| Interest coveragei | -- | -- | -- | -106.43 | -81.88 | -71.84 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and commercialization of precision therapies for genetically defined diseases100.00%
Region
United States100.00%
Quote time 2026-10-08 07:53:17 · For reference only, not investment advice and not tailored to your situation.